METASTATIC PROSTATE CANCER
Clinical trials for METASTATIC PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Promising combo for tough prostate cancer hits roadblock
Disease control TerminatedThis study tested a new drug, tazemetostat, combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in men with a hard-to-treat type of advanced prostate cancer that had stopped responding to hormone therapy. The goal was to find the best dose and see if…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
Engineered t cells take aim at hard-to-treat prostate cancer
Disease control TerminatedThis early-stage study tested a new treatment called BPX-601 for people with advanced prostate cancer that had stopped responding to other therapies. The treatment uses a patient's own immune cells, modified to recognize and attack cancer cells carrying a specific marker (PSCA). …
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 03:10 UTC
-
Promising prostate cancer treatment trial halted early
Disease control TerminatedThis study tested a new drug (177Lu-DOTA-rosopatamab) that delivers radiation directly to prostate cancer cells. It was for men with advanced prostate cancer that had stopped responding to hormone therapy. The trial aimed to see if adding this drug to standard care could slow can…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: PHASE3 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Ltd • Aim: Disease control
Last updated May 20, 2026 11:55 UTC
-
Prostate cancer imaging showdown: which drug hits tumors harder?
Knowledge-focused TerminatedThis early-stage study compared two radioactive drugs (177Lu rhPSMA-10.1 and 177Lu vipivotide tetraxetan, also known as Pluvicto) in 17 men with metastatic prostate cancer that cannot be cured. The goal was to see which drug delivers more radiation to tumors while sparing the kid…
Matched conditions: METASTATIC PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Blue Earth Therapeutics Ltd • Aim: Knowledge-focused
Last updated May 20, 2026 11:54 UTC